LEADER 05616nam 2200721Ia 450 001 9910819177303321 005 20230120004844.0 010 $a1-281-05582-4 010 $a9786611055820 010 $a0-08-048981-8 035 $a(CKB)1000000000365190 035 $a(EBL)294423 035 $a(OCoLC)476058534 035 $a(SSID)ssj0000261608 035 $a(PQKBManifestationID)11207494 035 $a(PQKBTitleCode)TC0000261608 035 $a(PQKBWorkID)10268835 035 $a(PQKB)10701652 035 $a(MiAaPQ)EBC294423 035 $a(Au-PeEL)EBL294423 035 $a(CaPaEBR)ebr10226588 035 $a(CaONFJC)MIL105582 035 $a(EXLCZ)991000000000365190 100 $a20070124d2007 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aTranslation of addictions science into practice /$fedited by Peter M. Miller and David J. Kavanagh 205 $a1st ed. 210 $aAmsterdam ;$aBoston $cElsevier/Pergamon$d2007 215 $a1 online resource (513 p.) 300 $aDescription based upon print version of record. 311 $a0-08-044927-1 320 $aIncludes bibliographical references and index. 327 $aFront cover; Translation of Addictions Science into Practice; Copyright page; Table of Contents; List of Contributors; Preface; Section I: Genetics and Neuroscience; Chapter 1. The Interplay between Genotype and Gene Expression in Human Brain: What Can it Teach Us about Alcohol Dependence?; Drug and Alcohol Abuse; Future Directions; Concluding Remarks; Acknowledgments; References; Chapter 2. Common Genetic Influences on Antisociality and Addictions: Implications for Clinical Science and Practice; Comorbidity of Addictions and Antisociality: An Introduction 327 $aShared Genetic Vulnerabilities to Antisociality and AddictionsMolecular Genetics of Antisociality and Addictions: Examples from the Study of Alcoholism; Implications of Common Genetic Influences of Antisocial Personality and Addictions for Conceptualizing and Classifying Psychopathology; From Genes to Clinical Practice: Implications of Genetic Research for Advancing Clinical Care; Summary and Conclusions; References; Chapter 3. Opioids, Pain and Addiction: Cause and Consequence; Opioid-Induced Hyperalgesia; Implications for Opioid Dependence Treatment; Future Directions; General Conclusion 327 $aReferencesChapter 4. Imbalance between Neuroexcitatory and Neuroinhibitory Amino Acids causes Craving for Ethanol: From Animal to Human being Studies; Introduction; Effects of Ethanol on Glutamate; Ethanol Withdrawal; Multiple Ethanol Withdrawal; Acamprosate and Repeated Ethanol Withdrawal; Conditioning Associated with Ethanol; Excitatory Amino Acids and Ethanol in Humans; Clinical Implications; References; Chapter 5. Cannabis and the Brain: Implications of Recent Research; Psychiatric Symptoms Associated with Cannabis; Cannabis and Schizophrenia; Summary and Future Directions; References 327 $aSection II: PharmacotherapyChapter 6. The Plasticity of Alcohol Addiction Suggests Novel Approaches to Pharmacological Intervention; Neurobiology of Alcohol Addiction; Glutamatergic System; Glutamate and Alcohol; Ethanol and the Post-Synaptic Density; Metabotropic Glutamate Receptors; References; Chapter 7. Pharmacotherapies for the Treatment of Alcohol Dependence: Current and on the Horizon; Epidemiology; Alcohol Withdrawal and Detoxification; Relapse Prevention; Disulfiram; Naltrexone; Acamprosate; Treatment Options on the Horizon 327 $aMedication Compliance and Its Impact on Alcohol PharmacotherapyConclusions and Future Directions; References; Chapter 8. Agonist Treatment for Stimulant Abuse and Dependence; Relevant Science, Introduction and Background; Immediate Implications for Prevention, Assessment or Treatment Developments; Speculation on Future Directions for Translational Developments; References; Chapter 9. Topiramate-Induced Neuromodulation of Cortico-Mesolimbic Dopamine: Implications for the Treatment of Nicotine and Alcohol Dependence; Nicotine and Alcohol Dependence:The Problem of Comorbidity 327 $aTopiramate: A Promising new Vista 330 $aRecent advances in the understanding of the genetic, neurochemical, behavioral and cultural underpinnings of addiction have led to rapid advances in the understanding of addiction as a disease. In fact, advances in basic science and the development of new pharmacological and behavioral therapies associated with them are appearing faster than can be assimilated not only by clinical researchers but practitioners and policy makers as well. Translation of science-based addictions knowledge into improved prevention, assessment and treatment, and communication of these changes to researchers and p 606 $aDrug abuse$xPhysiological aspects 606 $aSubstance abuse$xPhysiological aspects 606 $aDrug abuse$xTreatment 606 $aSubstance abuse$xTreatment 615 0$aDrug abuse$xPhysiological aspects. 615 0$aSubstance abuse$xPhysiological aspects. 615 0$aDrug abuse$xTreatment. 615 0$aSubstance abuse$xTreatment. 676 $a616.86/06 22 676 $a616.8606 676 $a616.8606 701 $aMiller$b Peter M$g(Peter Michael),$f1942-$01620620 701 $aKavanagh$b David John$01654556 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910819177303321 996 $aTranslation of addictions science into practice$94006462 997 $aUNINA